TIDMCREO

RNS Number : 6846L

Creo Medical Group PLC

20 April 2018

Creo Medical Group plc

Change of accounting reference date

Chepstow, Wales - 20 April 2018 - Creo Medical Group plc (AIM: CREO) ("Creo" or the "Company"), a medical device company focused on the emerging field of surgical endoscopy, announces that it has changed its accounting reference date from 30 June to 31 December with immediate effect.

As a result of the change of accounting reference date, the Company's reporting calendar will be as follows:

-- Unaudited interims for the 6 month period ending 30 June 2018 to be published by 30 September 2018; and

-- Audited results for the 18 month period to 31 December 2018 to be published by 30 April 2019.

Thereafter, interim and annual reports will be published each year for the 6 months to 30 June and 12 months to 31 December respectively, in accordance with the AIM Rules for Companies.

Contacts

 
 Creo Medical:          Cenkos:                                   FTI Consulting: 
 Richard Rees           Camilla Hume/Mark Connelly (NOMAD)        Brett Pollard / Mo Noonan 
  +44 (0)129 160 6005    Michael Johnson / Russell Kerr (Sales)    +44 (0)203 727 1000 
                         +44 (0)207 397 8900                       creo@fticonsulting.com

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSEMFISFASEDL

(END) Dow Jones Newswires

April 20, 2018 11:38 ET (15:38 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Creo Medical Charts.